Using computer-aided detection (CAD) software to help analyze and interpret mammograms does not improve accuracy, but it does raise a womans risk of being recalled for additional testing, according to a study published online July 27 in the Journal of the National Cancer Institute. An accompanying editorial suggested the need for further improvements in CAD software and described existing technology as more harmful than beneficial.

The Office of the National Coordinator for Health IT (ONC) has announced its "Summer Concert" series highlighting development work on distributed population queries.

The Society of Cardiovascular Computed Tomography (SCCT) announced the winners of the Toshiba Young Investigator Award at the organization's sixth annual scientific meeting July 14-17.

Two tiny genetic variations can predict which patients with Hodgkin's lymphoma are most likely to develop radiation-induced second cancers years after treatment, according to a genome-wide association study (GWAS) published online July 24 in Nature Medicine. Knowing in advance who is at risk could help physicians tailor treatment to reduce the risks for patients who are most susceptible to long-term damage.

Takeda Pharmaceuticals North America, maker of the thiazolidinedione (TZD) pioglitazone, has resubmitted new drug applications (NDA) in hopes of gaining approval from the FDA for alogliptin, an investigative dipeptidyl peptidase IV inhibitor (DPP-4i) to treat type 2 diabetes, and a fixed-dose combination therapy alogliptin/pioglitazone.

Most primary care physicians (PCPs) are confident in their abilities to provide cancer survivors with adequate follow-up care, an assurance in the skills of PCPs shared by less than one-fourth of oncologists, who see themselves as better-equipped to care for survivors. Meanwhile, both PCPs and oncologists order significantly more screening than professional guidelines recommend.

Health IT software developer Philips has released its latest dictation management software tool, SpeechExec Enterprise 4.0.

When researchers undertake porcine studies in the preclinical setting, it typically indicates a final step in the research process, which may soon after result in a new treatment method for patients.